Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


X-ray contrast imaging agent (e.g., computed tomography, angiography, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424900100 - IN VIVO DIAGNOSIS OR IN VIVO TESTING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424900450 Halogenated benzene ring containing 23
424900440 Hetero ring containing 22
424900420 Transition, actinide, or lanthanide metal containing 14
424900410 Barium containing 2
20100183521METHODS OF DETECTING AND TREATING COLON DISORDERS - The subject invention pertains to a method of detecting colon disorders including inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, based on underexpression of Lipopolysaccharide Responsive Beige-like Anchor (LRBA). Advantageously, the invention may be used to test for inflammatory bowel disease using a blood sample from a subject before a more invasive test for colon disorders is employed. The invention also pertains to methods of treating a colon disorder in a subject in which the colon disorder is detected.07-22-2010
20100047181MIXTURE OF A VANILLOID RECEPTOR AGONIST AND A SUBSTANCE INHIBITING NERVE REGENERATION, USE THEREOF FOR PRODUCING A PAINKILLER, AND METHOD FOR APPLYING SAID PAINKILLER - The following abstract will replace all prior versions of the abstract in the application: 02-25-2010
424900430 Carbohydrate or derivative thereof attached to or complexed with the agent 1
20100166668CT NEGATIVE CONTRAST MEDIUM OF AQUEOUS MATRIX FOR DIGESTIVE TRACT AND THE PREPARATION METHOD THEREOF - An aqueous negative contrast agent for CT imaging of the gastrointestinal tract and the preparation method thereof. The agent is used in biological and pharmaceutical field. Its components and the weight percent are: hydrogel matrix 0.01-1%, micro-/nano-particles of the materials with low densities 5-50%, stabilization agents 0.1-5%, the rest is deionized water. The preparation method is: stabilization agents are added into the hydrogel matrix made of natural or synthetic hydrophilic polymers, then micro-/nano-particles of the materials with low CT densities are added or prepared, and uniformly dispersed in the hydrogel matrix. The CT density of the resulted aqueous negative contrast agent for CT imaging of the gastrointestinal tract is −30HU to −500HU. It can decrease the CT density inside the intestine lumen to lower than −30HU. The intestine wall can be depicted clearly and the CT signals intensities inside lumen are uniform. It is feasible for 3D images processing such as virtual endoscopy reconstruction with the negative contrast agent. The agent is safe, stable and nontoxic. It will not lead to diarrhea after administration. It is of great significance for the improved sensitivity and specificity of CT diagnosis for the diseases on the intestinal wall and lumen.07-01-2010
Entries
DocumentTitleDate
20100086489OSTEOPENIA ANIMAL MODEL - The present invention provides a method for producing an osteopenia animal model by RANKL administration and an osteopenia animal model.04-08-2010
20090191128CORE-SHELL NANOPARTICLES FOR THEARAPY AND IMAGING PURPOSES - The invention relates to nanoparticles coated with an inorganic nanoscale material herein referred to as core-shell nanoparticle, in which the core material has a wider band gap than the shell material. The described core-shell nanoparticles are very suitable for the application in photodynamic therapy due to their enhanced energy transfer ability.07-30-2009
20100092392Pet Scanning Determination of Lymph Nodes Enriched in 124 I Labeled Antibodies for Cancer Patient Prognostication - A method for detecting antigen associated with adenocarcinoma commences by forming a 04-15-2010
20090047218Method for producing albumin conjugates comprising an X-ray contrast medium as the active substance - The invention concerns X-ray contrast medium-protein conjugates and in particular X-ray contrast medium-albumin conjugates, medicaments comprising X-ray contrast medium-protein conjugates, processes for the production of such conjugates as well as the use thereof.02-19-2009
20130071332LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE - Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.03-21-2013
20130071333METHOD AND SYSTEM FOR IDENTIFYING, ASSESSING, AND MANAGING CANCER GROWTH RATES AND POTENTIAL METASTASIS - Techniques described herein generally relate to identifying, assessing, and managing cancer growth rates and potential metastasis. Some example methods may include constructing one or more quantitative metrics for the potential metastasis in a selected population of other patients, acquiring a first set of numeric biomarker data for the patient before having placed a biomarker in the patient, acquiring a second set of numeric biomarker data for the patient after having placed the biomarker in the patient, determining a set of biomarker surrogate values for microvessel density information based on a mean numeric biomarker difference derived from the first set of numeric biomarker data and the second set of numeric biomarker data, determining a set of biomarker surrogate values for microvessel density information based on a mean numeric biomarker difference derived from the first set of numeric biomarker data and the second set of numeric biomarker data, and predicting quantitative and objective risk for the cancer growth rates and potential metastasis and adjusting a treatment plan based on the biomarker surrogate values and at least one of the one or more quantitative metrics.03-21-2013
20130071334METHOD AND SYSTEM FOR IDENTIFYING, ASSESSING, AND MANAGING CANCER DISEASE - Techniques described herein generally relate to identifying, assessing, and managing cancer diseases. Some example methods may include constructing one or more quantitative metrics for the cancer disease in a selected population of other patients retrieved during the scheduling interval, acquiring a first set of numeric biomarker data for the patient before having placed a biomarker in the patient, acquiring a second set of numeric biomarker data for the patient after having placed the biomarker in the patient, identifying one or more nodules from the first set of numeric biomarker data and the second set of numeric biomarker data, wherein each of the one or more nodules is characterized by a mean numeric biomarker difference value derived from the first set of numeric biomarker data and the second set of numeric biomarker data, and predicting quantitative and objective risk for the one or more nodules based on the mean numeric biomarker difference value and at least one of the one or more quantitative metrics.03-21-2013
20100189656CONTRAST AGENTS - The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a triamine alkyl central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds.07-29-2010
20090202441COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS - The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin.08-13-2009
20090311192CORE AND CORE-SHELL NANOPARTICLES CONTAINING IODINE FOR X-RAY IMAGING - Nanoparticles having an average particle size of less than 2000 nm, wherein said nanoparticles comprise a polymer having pendant cleavable iodine substituted groups are provided. Processes for preparing the nanoparticles and their use as a contrast agent for X-ray imaging are also described.12-17-2009
20080206147Method for the Use of [11C]Carbon Monoxide in Labeling Synthesis of 11C-Labelled Acids by Photo-Induced Free Radical Carbonylation Under Mild Conditions Using Sulfoxides - Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with sulfoxides and triethylamine are provided. The resultant carbon-isotope labeled acids, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method for PET studies are also provided.08-28-2008
20100272649Bioactive Bone Cement and Method for Its Production - A bioactive PMMA (polymethylmethacrylate) bone cement contains a powder component and a reactive monomer liquid, wherein the powder component and the reactive monomer liquid when mixed with one another react with one another and form a polymer-based solid material. The powder component contains particulate polymer powder of polymethylmethacrylates; a radical starter; and anionic copolymer nanoparticles. The anionic copolymer nanoparticles are distributed in nano-particulate form within the particulate powder component or coated as a film on particles of the particulate polymer powder.10-28-2010
20080317673METHOD FOR DIAGNOSING AND TREATING BRONCHIAL ASTHMA - A method for diagnosing and treating a bronchial asthma by classifying a patient's asthma as Type I, Type II or Type III based on the patient's symptoms is disclosed. The symptoms for the three types of asthma are disclosed together with recommended treatment guidelines for each type to optimize treatment regiments based on symptoms.12-25-2008
20090246141HIGHER FATTY ACID TRIESTER AND AMIDE DERIVATIVE HAVING DIETHYLENETRIAMINE-TYPE METAL CHELATE STRUCTURE - A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) wherein R10-01-2009
20090246142Triggered Self-Assembly of Nanoparticles In Vivo - The present invention provides triggered self-assembly nanosystems. Such nanosystems comprise a population of triggered self-assembly conjugates, each conjugate comprising one or more monomeric units and one or more complementary binding moieties. In some embodiments, inventive nanosystems and conjugates can be used to treat and/or diagnose a disease, disorder, and/or condition.10-01-2009
20100021389RADIOGRAPHIC CONTRAST AGENT FOR POSTMORTEM, EXPERIMENTAL AND DIAGNOSTIC ANGIOGRAPHY - A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterised in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents.01-28-2010
20080279779CT tomographic imaging process and system - A CT radiographic imaging process implements a processing operation on images in order to detect the use of a saline solution. When a saline solution is detected, it extracts a component or a portion of a component that does not appear to be contrasted in the initial images, for example, in the case of cardiac imaging, the right cavity of the heart. The imaging system comprises means for implementing this process.11-13-2008
20080267881IMAGING AGENTS - The invention relates to compounds of formula (I): and their use as targeting vectors that bind to receptors associated with angiogenesis. Such compounds may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma.10-30-2008
20110020237Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders - Compositions of matter and methods for inhibiting drusen or drusen-like deposits and/or for treating diseases related to drusen or drusen-like deposits in human or animal subjects by administering to the subject a therapeutically effective amount of i) a conformational epitope of an aggregate that contributes to the formation or biosynthesis of drusen or drusen-like deposits and/or ii) an antibody that binds to a conformational epitope of an aggregate that contributes to the formation or biosynthesis of drusen or the drusen-like deposit.01-27-2011
20110020238STABILIZING AQUEOUS SOLUTION OF IODINE CHLORIDE BY ADDING SODIUM CHLORIDE - This invention relates generally to non-ionic X-ray contrast agents. It further relates to the preparation of iodine chloride, a key reagent in the synthesis of non-ionic X-ray contrast agents such as iodixanol and iohexol. In particular, the iodine chloride is produced in a reaction involving iodine, sodium chlorate, and hydrochloric acid as the starting materials. The instant invention relates to a method of stabilizing aqueous iodine chloride solutions by adding about one to about four molar equivalents of sodium chloride relative to sodium chlorate to an aqueous reaction mixture of sodium chlorate, hydrochloric acid, and iodine.01-27-2011
20110052503BIODEGRADABLE CONTRAST AGENTS - The present invention provides a radio-opaque composition comprising a cleavable, preferably enzymatically-cleavable, derivative of a physiologically tolerable organoiodine compound and a non-acrylic polymer wherein said derivative is incorporated in said non-acrylic polymer.03-03-2011
20100158811ASSESSING BRAIN ANEURYSMS - This document provides methods and materials related to assessing brain conditions within mammals. For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) with a brain aneurysm is likely to experience brain aneurysm rupture are provided.06-24-2010
20100028264LTBP2 AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.02-04-2010
20090208417Detection and Localized Imaging of Cancer Using X-Ray Fluorescent Nanoparticle/Preferential Locator Conjugates - A method for detecting gold or other nanoparticles conjugated to preferential locators commences by contacting tissue suspected of being neoplastic with gold nanoparticle/preferential locator conjugates for a time adequate for the conjugates to bind with the tissue. A beam of gamma photons (such as from, 08-20-2009
20080267882Imaging compounds, methods of making imaging compounds, methods of imaging, therapeutic compounds, methods of making therapeutic compounds, and methods of therapy - Embodiments of the present disclosure provide for RGD compounds that include a multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide, methods of making the RGD compound, pharmaceutical compositions including RGD compound, methods of using the RGD compositions or the pharmaceutical compositions including RGD compositions, methods of diagnosing and/or targeting angiogenesis related disease and related biological events, kits for diagnosing and/or targeting angiogenesis related disease and related biological events, and the like. In addition, the present disclosure includes compositions used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging) of the RGD compounds in vivo.10-30-2008
20120003159COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING - Examples of compositions of liposomes and methods of making the same containing high concentrations of contrast-enhancing agents for computed tomography are provided. Example compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes stable, that is, resistant to leakage of the contrast-enhancing agents, including the extrusion of the liposomes at high pressures and at high flow rates per total pore area of the extrusion filters.01-05-2012
20120076734RADIOPAQUE ANTIBIOTIC DENTAL PASTE AND USES THEREOF - Compositions useful for disinfecting a dental wound are described. The compositions include an active ingredient comprising one or more antibiotics, a radiopaque substance, and optionally a pharmaceutically acceptable excipient. Methods for treating dental wound sites with the compositions are also described.03-29-2012
20120328528MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER PRDX4 AND USE THEREOF - [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth.12-27-2012
20080233049Agents And Methods For Early Diagnosis And Monitoring Of Alzheimer's Disease And Other Neurological Disorders - This invention is in the fields of medicine and neurology, and relates to methods and agents for early diagnosis and monitoring of Alzheimer's disease and other neurological disorders. More particularly, the present invention provides the method for evaluating the health of central nervous system neurons in a human patient, comprising the steps of: a) administering to said patient a population of molecular complexes comprising (i) a polypeptide capable of activating neuronal endocytosis, axonal transport, and synaptic transfer; and (ii) an imaging agent suited for determining location and evaluating neuronal transport of said molecular complexes within said patient; and b) using at least one imaging method to determine location and evaluate neuronal transport of said molecular complexes within said patient.09-25-2008
20080199402Contrast Agents - The present invention relates to iodine containing compounds containing a central cyclopropane scaffolding moiety allowing for the arrangement of three iodinated phenyl groups bound thereto.08-21-2008
20120027687FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE - The present disclosure provides a method for treating stroke by administering an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C(PKC) activator, wherein the PKC activator may be administered before, after, or at the same time as the rTPA. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are compositions and kits comprising rTPA and a PKC activator for treating stroke.02-02-2012
20130202535X-RAY VISIBLE MEDICAL DEVICE AND PREPARATION METHOD THEREOF - The present invention relates to an X-ray visible medical device comprising a medical device and a layer bound onto the medical device, wherein the layer is composed of an X-ray contrast material or a composite of the X-ray contrast material and a biocompatible polymer. Also disclosed is a method for preparing the X-ray visible medical device.08-08-2013

Patent applications in class X-ray contrast imaging agent (e.g., computed tomography, angiography, etc.)

Patent applications in all subclasses X-ray contrast imaging agent (e.g., computed tomography, angiography, etc.)